1:15 pm Next Generation Tetravalent Bispecific Antibodies for Cancer Immunotherapy
Time: 1:15 pm
day: Conference Day One
Details:
- Discover F-star’s unique approach to making bispecific tetravalent antibodies in the Fc
- Description of the process to produce a conditional CD137 agonist Fcab
- FS222 bispecific uses of the CD137 agonist Fcab, in combination with a PD-L1 targeting Fab
- Discuss the benefits of FS222 in being tetravalent
